Investigational drug · Phase 3
Bemarituzumab
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Gastric Cancer, Gastroesophageal Junction Adenocarcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
19
Any phase or sponsor naming "Bemarituzumab"
First trial start
2022
Mar 7, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Bemarituzumab", any sponsor or status.
- Phase 210
Conditions studied
As listed on its trial records.
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
Approved drugs for the same conditions: Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Bemarituzumab" as an intervention, largest first.
- Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT05052801 · 547 participants · Start Mar 7, 2022 · Primary completion Jun 20, 2025
Drug: Bemarituzumab; mFOLFOX6 and 1 more · For: Gastric Cancer; Gastroesophageal Junction Adenocarcinoma
Sites: Anchorage, Alaska; Phoenix, Arizona; Cerritos, California · 300 sites in all
- Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.Pivotal-lookingTerminated
AmgenAmgen (AMGN)
NCT05111626 · 515 participants · Start Mar 14, 2022 · Primary completion Oct 14, 2025
Drug: Bemarituzumab; Nivolumab and 1 more · For: Gastric Cancer; Gastroesophageal Junction Adenocarcinoma
Sites: Phoenix, Arizona; Cerritos, California; Downey, California · 348 sites in all
AmgenAmgen (AMGN)
NCT05325866 · 260 participants · Start Sep 23, 2022 · Primary completion Jan 28, 2026
Drug: Bemarituzumab · For: Solid Tumors
Sites: Duarte, California; Orange, California; Aurora, Colorado · 115 sites in all
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT06767800 · 204 participants (planned) · Start Nov 21, 2024 · Primary completion Sep 2026
Drug: TQB2102 for injection (7.5 mg) +Benmelstobart+Chemotherapy; TQB2102 for injection (6 mg/7.5 mg) +Benmelstobart+Chemotherapy and 1 more · For: Gastroesophageal Adenocarcinoma
Sites: Fuyang, China; Lu'an, China; Maanshan, China · 39 sites in all
- A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction CancerPivotal-lookingCompleted
Five Prime Therapeutics, Inc.Industry
NCT03694522 · 155 participants · Start Sep 14, 2018 · Primary completion Sep 23, 2020
Drug: Bemarituzumab; Placebo and 1 more · For: Gastric Cancer
Sites: Tucson, Arizona; Greenbrae, California; Sacramento, California · 189 sites in all
University of ChicagoAcademic, hospital or other
NCT02213289 · 80 participants · Start Jan 20, 2015 · Primary completion Feb 1, 2020
Drug: Trastuzumab; ABT-806 and 4 more · For: Adenocarcinoma
Sites: Chicago, Illinois
Five Prime Therapeutics, Inc.Industry
NCT02318329 · 79 participants · Start Nov 2014 · Primary completion Feb 28, 2019
Drug: FPA144 · For: Advanced Solid Tumors; Gastric Cancer; Transitional Cell Carcinoma of the Bladder
Sites: Duarte, California; Los Angeles, California; San Francisco, California · 26 sites in all
AmgenAmgen (AMGN)
NCT05267470 · 74 participants · Start Mar 29, 2022 · Primary completion May 28, 2024
Drug: Bemarituzumab; Docetaxel and 4 more · For: Squamous-Cell Non-Small-Cell Lung Cancer
Sites: Orange, California; Morristown, New Jersey; The Bronx, New York · 39 sites in all
AmgenAmgen (AMGN)
NCT05322577 · 72 participants · Start May 17, 2022 · Primary completion Nov 21, 2025
Drug: Bemarituzumab; CAPOX and 2 more · For: Gastric Cancer; Gastroesophageal Junction Cancer
Sites: Northport, New York; Toyoake-shi, Japan; Hirosaki-shi, Japan · 42 sites in all
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06897579 · 40 participants · Start Apr 7, 2025 · Primary completion Apr 15, 2026
Drug: Carboplatin for injection/cisplatin for injection + etoposide injection + benmelstobart injection + Anlotinib hydrochloride capsule; Carboplatin for injection/Cisplatin for injection + etoposide injection + Tislelizumab injection · For: Extensive Stage Small Cell Lung Cancer
Sites: Maanshan, China; Beijing, China; Quanzhou, China · 32 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- FGFR2b as a Therapeutic Biomarker in Gastric Cancer: Lessons from Bemarituzumab and Implications for Next-Generation Targeted Therapy.
Sagawa T, Hirakawa M, Nagashima H, et al. · Curr Oncol Rep 2026
- CLDN18 and FGFR2 splicing variants are emerging tumor-associated antigens for cancer therapy.
Katoh M, Katoh M · Front Mol Med 2026
- Current and Emerging Targeted Therapy in Advanced Gastroesophageal Adenocarcinoma.
Oakley O, Mahmood U, Ahmad Y, et al. · Pharmaceuticals (Basel) 2026
- FGFR2 amplification and fusion identified by NGS align with FGFR2b overexpression.
Hwang I, Kim DG, Kim Y, et al. · Virchows Arch 2026
- Global prevalence of FGFR2b protein overexpression in advanced gastric cancer and gastroesophageal junction cancers: pooled analysis of two bemarituzumab phase III studies.
Maron SB, Xu RH, Wainberg ZA, et al. · ESMO Open 2026
- Bemarituzumab Suppresses Choroidal Neovascularization in Mice by Downregulating Melanoma Cell Adhesion Molecule and Yes-Associated Protein 1.
Ding L, Xie B, Lv J, et al. · ACS Pharmacol Transl Sci 2026
Also in development for Gastric Cancer
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- ApatinibRIVO, RivoceranibPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · Gastric Cancer, HCC, Hepatocellular Carcinoma
- CamrelizumabSHR-1210, CAMPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- Tegafur-gimeracil-oteracil potassiumS-1, tegafurPhase 38 trials
Ono Pharmaceutical Co., Ltd. · Gastric Cancer, Esophageal Cancer, Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
- AZD0901Sonesitatug vedotin, CMG901Phase 36 trials
AstraZeneca · Gastric Cancer, Gastroesophageal Junction Cancer, Gastroesophageal Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Amgen.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.